Maxigesic approval positive for AFT Pharmaceuticals

Maxigesic approval positive for AFT Pharmaceuticals
AFT founder and managing director Hartley Atkinson. (Image: Supplied)
Tamara Poi-Ngawhika
 AFT Pharmaceuticals, the owner of Maxigesic, offers investors a “large opportunity but with a high degree of uncertainty”, according to Forsyth Barr analysts.The New Zealand stock exchange-listed company has just announced its rapid-release tablet form of Maxigesic has been granted approval by the United States Food and Drug Administration (FDA) for use in the country.Breaking into the US market is difficult because getting FDA approval can be challenging. AFT said the US market is worth about US$7.16 billion (NZ$11.5b) and is...

More Markets

Eroad shares slump 23% as it shifts focus from North America
Markets

Eroad shares slump 23% as it shifts focus from North America

Eroad cuts North America exposure, impairing $150m in assets.

$55m deal secures Santana mining land
Primary Sector

$55m deal secures Santana mining land

The gold miner now owns all the land where its best mining prospects lie.  

Quashed opens the door for challenger insurers
Markets Risky Business

Quashed opens the door for challenger insurers

Turners-backed comparison site could hit key milestone by year-end.

Fonterra’s fascinating exec incentive scheme
Opinion

Stock & Trade: Fonterra’s fascinating exec incentive scheme

Winston Peters has questioned bonuses linked to Fonterra’s $4.2b sale.